As Stelara Sunset Begins, J&J Says Tremfya Will Step Up
Sales of Johnson & Johnson’s Stelara declined 6.6% in the third quarter as the first biosimilars launched in Europe and US sales were softer than expected.
Sales of Johnson & Johnson’s Stelara declined 6.6% in the third quarter as the first biosimilars launched in Europe and US sales were softer than expected.